May 14, 2024 ProMIS Neurosciences Announces First Quarter 2024 Financial Results and Recent Highlights
Apr 30, 2024 ProMIS Neurosciences Publishes Study Highlighting Oligomer Selectivity and Benefit of Amyloid-Beta-Directed Antibodies
Apr 9, 2024 ProMIS Neurosciences Publishes in the Journal of Biological Chemistry on the Interaction Between Pathogenic Proteins as a Treatment Target for ALS
Jan 22, 2024 ProMIS Neurosciences Achieves Milestone in Development of Therapeutic Alpha-Synuclein Vaccine